The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal, or bone metastases in the phase II VISION trial.
 
Niels Reinmuth
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Pfizer; Roche; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Merck KGaA; Pfizer; Roche; Sanofi; Takeda
 
Julien Mazieres
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; Hengrui Therapeutics; Lilly/ImClone; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Sanjay Popat
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Guardant Health; Janssen; Lilly; Merck KGaA; Novocure; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; EQRx; GlaxoSmithKline; Guardant Health; IO Biotech; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - Amgen (Inst); ARIAD (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trizell (Inst); Turning Point Therapeutics (Inst)
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Emma S Hook
Employment - Delta Hat Ltd.
 
Anthony Hatswell
Employment - Delta Hat Ltd.
 
Soetkin Vlassak
Employment - Merck KGaAMerck N.V.-S.A, Hoeilaart, Belgium, an affiliate of Merck KGaA, Darmstadt, Germany
 
Andreas Johne
Employment - Merck KGaA
Stock and Other Ownership Interests - Merck KGaA
 
Helene Vioix
Employment - Merck KGaA
 
Paul K. Paik
Honoraria - AstraZeneca; Bicara Therapeutics; EMD Serono; Janssen Oncology; Takeda
Consulting or Advisory Role - AstraZeneca; Bicara Therapeutics; EMD Serono; Janssen Oncology; Takeda
Research Funding - Bicara Therapeutics; Boehringer Ingelheim; EMD Serono